Famotidine
Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. (In Vitro) :Famotidine (MK-208) is a histamine H2-receptor antagonist that inhibits stomach acid production, and it is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD) . Famotidine (MK-208) Group (2 mg/kg/day) were significantly lower than the equivalent parameters for the Control Group on both the third and seventh days post-surgery. Famotidine (MK-208) exerts detrimental effects on the anastomotic bursting pressure and hydroxyproline content of perianastomotic tissues in the colon of rats. Famotidine (MK-208) increased the transgastric potential difference (PD) and promoted the recovery of decreased transgastric PD induced by acidified ethanol in rats. The preventive effect of famotidine on gastric lesions is attributable not only to suppression of acid secretion but to activation of the gastric mucosal defensive mechanisms.
Product Specifications
CAS Number
76824-35-6
Product Name Alternative
MK-208 | YM-11170
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
DMSO: 67 mg/mL (198.54 mM)
Smiles
N/C (N) =N\C1=NC (CSCC/C (N) =N/S (=O) (N) =O) =CS1
Molecular Formula
C8H15N7O2S3
Molecular Weight
337.45
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
(Z) -3- (((2- ((diaminomethylene) amino) thiazol-4-yl) methyl) thio) -N'-sulfamoylpropanimidamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
FITC-Linked Polyclonal Antibody to Fc Fragment Of IgG Low Affinity IIIa Receptor (FcgR3A)
FITC-Linked Polyclonal Antibody to Fc Fragment Of IgG Low Affinity IIIa Receptor (FcgR3A)